trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
    Enrollment open, Trial completion date, Trial primary completion date, Metastases:  A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors (clinicaltrials.gov) -  May 18, 2022   
    P1,  N=114, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Jun 2023
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
    New P2 trial, Combination therapy, Metastases:  A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer (clinicaltrials.gov) -  Apr 28, 2022   
    P2,  N=402, Not yet recruiting, 
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
    Enrollment open, Metastases:  A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) -  Jun 4, 2021   
    P1/2,  N=120, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Jun 2023 Not yet recruiting --> Recruiting
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
    Enrollment open, Metastases:  A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov) -  Oct 19, 2020   
    P1,  N=226, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting